Troy A. Ignelzi - 26 Jun 2026 Form 4 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Reporting relationship: Director
Issuer ticker: CTNM
Reported as of: 26 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jun 2026, 17:43:48 UTC
Prior SEC filing: 06 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Peter Slover, Attorney-in-Fact

Key filing fact

Troy A. Ignelzi filed Form 4 for Contineum Therapeutics, Inc. (CTNM) on 26 Jun 2026.

Key facts

This page summarizes Troy A. Ignelzi's Form 4 filing for Contineum Therapeutics, Inc. (CTNM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Jun 2026, 17:43.

Change

Previous filing in this sequence was filed on 06 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001579829 Primary reporting owner

Ignelzi Troy A.

Relationship: Director
Address: 3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Signature: /s/ Peter Slover, Attorney-in-Fact
Signature date: 26 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTNM transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +19,000
Change %
Price: $0.000000^*
Shares after: 19,000
Date: 26 Jun 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 19,000
Exercise price: $14.19
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.